BioCryst Pharmaceuticals, Inc.

NEWS

Drug Development

Clinical Catch-up from Last Week: May 20-24

Here’s a roundup of some of the top clinical trial news from the previous week.

May 24, 2019

7 min read

Mark Terry

Drug Development

Shares of BioCryst Fall After Phase III HAE Drug Underwhelms Investors

Despite hitting endpoints in the late-stage trial, BioCryst’s BCX7353 results do not stack up against Takeda’s Takhzyro, which was approved last year.

May 21, 2019

2 min read

Alex Keown

Policy

CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile

BioCryst Pharmaceuticals, Inc. today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period.

September 10, 2018

3 min read

end of relations(special f/x,made from my images)

Deals

Idera Pharma and BioCryst Pharma Get a Divorce Before the Wedding

Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018 to merge the two companies. Now the two companies announced the deal has been terminated.

July 11, 2018

3 min read

Mark Terry

FDA

European Regulators Make Decisions on Several Companies’ Drugs

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) announced a string of approvals, as well as a couple rejections.

February 26, 2018

2 min read

Mark Terry